Images List Premium Download Classic

Fatty Liver

Fatty Liver-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
5-ht2c receptor agonists and compositions and methods of use
Arena Pharmaceuticals, Inc.
July 05, 2018 - N°20180186797

Provided in some embodiments are compounds herein. Also provided in some embodiments are methods for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, prader-willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting ...
Novel composition for nonalcoholic fatty liver disease (nafld)
Cadila Healthcare Limited
July 05, 2018 - N°20180185330

The present invention provides a compound of formula (i) or pharmaceutical acceptable thereof, wherein ‘r’ is herein described. In addition, the invention relates to composition comprising effective therapeutic amount of compound of formula (i) and methods of using the compounds for treating or prevention disorder such as nonalcoholic fatty liver disease (nafld) including fatty liver (steatosis), nonalcoholic steatohepatitis (...
Compositions and methods for diagnosis and treatment of inflammation
The United States Of America As Represented By The Secretary Of The Navy
July 05, 2018 - N°20180185316

Compositions including an fatty acid, such as an odd chain fatty acid or a very long even chain fatty acid, and salts and derivatives thereof, and methods for treatment and prophylaxis of conditions related to inflammation and conditions related to inflammation, including anemia of chronic disease, insulin resistance, metabolic syndrome, autoimmune disease, hypertension, diabetes, nonalcoholic fatty liver disease, cardiovascular disease, ...
Fatty Liver Patent Pack
Download + patent application PDFs
Fatty Liver Patent Applications
Download + Fatty Liver-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Fatty Liver-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Human glut5 specific inhibitors and methods of treatment
Rosalind Franklin University
June 21, 2018 - N°20180170897

The present invention relates to compounds which have been discovered to be potent ligands (inhibitors) of human glut5 (glucose transporter type 5), a facilitative glucose transporter that transports fructose, and their use as ligands assays which can uncover additional ligands of glut5, having the potential for being used as drugs. In addition, the present invention is directed to compounds, chemical compositions ...
Use of a statin compound as local drug for treating obesity, diabetes, hypertension and hyperlipemia
Peking University Third Hospital
June 21, 2018 - N°20180169093

The invention discloses a use of a statin compound in the preparation of local drugs for improving lipid metabolism and treating obesity, hypertension, hyperlipidemia, fatty liver and hyperglycemia; and statin compound local compositions for improving lipid metabolism and treating obesity, hypertension, fatty liver, hyperlipidemia, atherosclerosis, coronary heart disease, apoplexy and other cardiovascular and cerebrovascular diseases, and drug formulation and preparation ...
Rumen protected glucose and method of preparation
June 21, 2018 - N°20180169026

The present disclosure provides a preparation method of rumen protected glucose, comprising the following steps: (1) preparing glucose into a pellet and drying; (2) fluidizing the pellet in a fluidized bed after drying; and (3) coating melted aliphatic alcohol and/or saturated fatty acid onto the surface of the pellet located in the fluidized bed to obtain a rumen protected bypass glucose particle. ...
Fatty Liver Patent Pack
Download + patent application PDFs
Fatty Liver Patent Applications
Download + Fatty Liver-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Fatty Liver-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Non-alcoholic fatty liver disease biomarkers
The Regents Of The University Of California
June 07, 2018 - N°20180155787

Methods, compositions, kits, and systems for characterizing the non-alcoholic fatty liver disease (nafld) state of a subject are provided. In some embodiments the methods, compositions, kits, and systems comprise at least one mirna selected from the differentially expressed mirnas listed in at least one of tables 1-4, 10-14, and 28-29.
Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty ...
Metabolic Technologies, Inc.
June 07, 2018 - N°20180153827

Methods and compositions for use in treating, preventing or improving diseases related to the liver in an animal, including but not limited to nonalcoholic fatty liver disease (nafld), alcoholic liver disease (ald) or nonalcoholic steatohepatitis (nash), are described. The compounds of the present invention are gamma-ketoaldehyde scavengers..
System and method for generating nonalcoholic fatty liver disease activity score (nas) using magnetic resonance ...
Mayo Foundation For Medical Education And Research
May 24, 2018 - N°20180140219

The present disclosure relates to a system and method for non-invasively determining nafld activity scores (nas) in patients using mechanical properties determined through magnetic resonance elastography (mre) imaging. The non-invasively determined nas score is then used to diagnose nfald and nash patients..
Analogues of vdac1-derlved peptides
The National Institute For Biotechnology In The Negev Ltd.
May 17, 2018 - N°20180134760

The present invention relates to peptides comprising analogues of vdac1-derived peptides having improved pharmacokinetic characteristics compared to the native parent peptides, which are effective in impairing cell energy production, in inducing apoptosis and cell death, particularly of cancerous cells, in eliminating cancer stem cells and in reducing symptoms associated with fat accumulation in liver cells particularly with nonalcoholic fatty ...
Novel cholesterol metabolite, 5-cholesten, 3beta-25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, ...
Virginia Commonwealth University
May 10, 2018 - N°20180127457

5-cholesten, 3β,25-diol, disulfate (25hcds) has been found to be an authentic pparγ agonist and lxr antagonist, and is used for the therapy of lipid disorders and inflammatory diseases, including without limitation fatty liver, inflammatory bowel, and atherosclerotic diseases.. .
Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination ...
Volant Holdings Gmbh
May 10, 2018 - N°20180125870

The present invention is directed to pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of an array of the manifestations of metabolic syndromes, including type 2 diabetes, hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the ...
Treatment for hepatic fibrosis
Galmed Research And Development Ltd.
May 10, 2018 - N°20180125862

The invention relates to the treatment and reduction of fibrosis, specifically hepatic fibrosis. More specifically, embodiments of the invention provide compositions and methods useful for the treatment and inhibition of hepato-fibrotic conditions associated with non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash), employing the use of 3β-arachidylamido-7α,12α-dihydroxy-5β-cholan-24-oic acid (...
Fatty Liver Patent Pack
Download + patent application PDFs
Fatty Liver Patent Applications
Download + Fatty Liver-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Fatty Liver-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Methods of treating liver disease using indane acetic acid derivatives
T3d Therapeutics, Inc.
May 03, 2018 - N°20180117013

This invention describes the use of indane acetic acid derivatives which are dual ppar delta/gamma agonists for the treatment of liver diseases including one or more of the following: nafld (non alcoholic fatty liver disease), nash (non alcoholic steatohepatitis), farber's disease, aclf (acute-on-chronic liver failure), clf (chronic liver failure), polt-hcv-svr (post-orthotopic liver transplant due to hepatitis c virus infection ...
Methods and compositions for preventing or treating fatty liver, protecting liver function or ameliorating liver ...
Sinew Pharma Inc.
May 03, 2018 - N°20180117003

The present invention relates to methods and compositions for preventing or treating fatty liver, protecting liver function or ameliorating liver diseases caused by fatty liver or other associated disorders.. .
Modulators of farnesoid x receptor and methods for the use thereof
Xiamen University
May 03, 2018 - N°20180116993

Compounds, compositions and methods are provided for treating the fxr-mediated disease or process in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound claimed, wherein the fxr-mediated disease or condition linked to chronic liver diseases such as nonalcoholic fatty liver disease and nonalcoholic steatohepatitis; gastrointestinal diseases; cardiovascular diseases; metabolic diseases such as diabetes and obesity; ...
Female menopause alleviation use of composition containing composite extract of red clover and pomegranate as ...
Hlscience Co .. Ltd
April 19, 2018 - N°20180104296

The present invention relates to: a natural composition containing a composite extract of pomegranates and red clover, exhibiting synergistic effects with respect to a menopausal symptom alleviation effect, an estrogen-like effect, an anti-obesity effect, a hyperlipidemia inhibitory effect, a fatty liver protective effect, an osteoporosis inhibitory effect and the like without any side effects; and various uses thereof, in particular, ...
Pharmaceutical composition containing silibinin and pueraria root extract
Tasly Pharmaceutical Group Co., Ltd.
April 19, 2018 - N°20180104216

Disclosed are a pharmaceutical composition for treating non-alcoholic fatty liver and a method for preparing same. The composition is prepared from the following hulk drugs by weight ratio: 8.75-60 parts of silibinin, 15-65 parts of phospholipid, 25-200 parts of pu'er tea extract, and 5-50 parts of radix puerariae extract..
Pharmaceutical composition containing silybin and l-carnitine
Tasly Pharmaceutical Group Co., Ltd.
April 19, 2018 - N°20180104215

A pharmaceutical composition for treating non-alcoholic fatty liver diseases. The pharmaceutical composition is prepared from 8.75-60 parts by weight of silybin, 15-65 parts by weight of phospholipid, 25-150 parts by weight of a pu'er tea extract, and 10.425-60 parts by weight of l-carnitine..
Method for discriminating symptom of hepatic disease
Sumitomo Dainippon Pharma Co., Ltd.
April 12, 2018 - N°20180100867

Provided is a noninvasive method for determining the presence of a symptom of a hepatic disease such as nonalcoholic fatty liver disease with a higher diagnostic accuracy. A method for discriminate between nonalcoholic fatty liver (nafl) and nonalcoholic steatohepatitis (nash), the method comprising: (1) a step of measuring the quantities of marker molecules contained in blood collected from a subject; (2) a ...
Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of ...
Volant Holdings Gmbh
April 12, 2018 - N°20180099001

The present invention is directed to a system characterization of nash that combines modeling and biomarkers, enabling pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of non alcoholic fatty liver disease (nafld) and non alcoholic steatohepatitis (nash). Said conditions are liver related complications among the array of manifestations of metabolic syndromes, including type 2 ...
Loading